Novo Nordisk's stock price decline has widened. Currently, the decline has exceeded 5%, with a cumulative decline of 10% since the beginning of the year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.